About clonoSEQ

A test that keeps up with today’s cancer treatments

clonoSEQ is a blood or bone marrow test1 that measures your child’s cancer at the deepest level currently available1-3, helping your child’s doctor make more informed decisions about their care. It is FDA-cleared in bone marrow and CLIA-validated in peripheral blood for B-cell acute lymphoblastic leukemia (B-ALL).

clonoSEQ is a blood or bone marrow test1 that measures your child’s cancer at the deepest level currently available1-3, helping your child’s doctor make more informed decisions about their care. It is FDA-cleared in bone marrow and CLIA-validated in peripheral blood for B-cell acute lymphoblastic leukemia (B-ALL).

clonoSEQ helps your child’s doctor tailor treatment to your needs

clonoSEQ uses next-generation sequencing technology, an advanced testing method that decodes your cancer’s genetic information, to look for unique cancer DNA sequences that serve as “barcodes.” After your child’s diagnosis, clonoSEQ identifies and counts their cancer’s unique “barcodes.” During treatment and remission, clonoSEQ can tell your child’s doctor if and how the number of “barcodes” has changed since your last MRD test.1

clonoSEQ is covered by Medicare and other major insurance providers

“clonoSEQ has truly changed our practice for patients with leukemia for the better.”

— Dr. Greg Yanik
C.S. Mott Children’s Hospital, University of Michigan Health

clonoSEQ can find 1 cancer cell among a million healthy cells1*

What does 1 in a million mean? It means that you know exactly where your child is in their journey. By precisely tracking MRD both during and after treatment, you and your child’s doctor can be more informed about their response to therapy—and can plan next steps accordingly.

*If sufficient sample material is provided.

clonoSEQ can identify residual disease that other tests miss4

Your child’s doctor will likely order other tests to monitor your child’s cancer. This is a good thing! It means they’re trying to gather as much information as possible. To best understand how your child’s cancer may be changing over time, these tests can be paired with highly sensitive MRD testing tools like clonoSEQ.2-7

clonoSEQ detected MRD in

39%

of patients who were deemed
MRD-negative by other testing5

Measure, then treat. Treat, then measure.
Repeat throughout your journey.

There are several stages of treatment for pediatric ALL. Your child’s doctor may want to monitor MRD with clonoSEQ after each type of treatment, to see how effective it was. Your child’s results may guide the choice of which treatment comes next.

Click through to see when your child’s doctor may test them with clonoSEQ.

(1 of 5)

Initial diagnosis1

Identify cancer cell DNA
(Clonality (ID) Test)
This clonoSEQ test provides a baseline. Because this test will have the largest number of cancer cells, it helps clonoSEQ know which cells to track over time in subsequent MRD tests.

(2 of 5)

After induction therapy8

This first part of your child’s treatment usually includes chemotherapy and corticosteroids. MRD results can guide your child’s doctor in deciding how strong the next stage of treatment should be.

(3 of 5)

After consolidation therapy8

This course of chemotherapy helps make your child’s previous chemotherapy treatment work better. clonoSEQ results can help your child’s doctor decide whether a stem cell transplant is needed.

(4 of 5)

After stem cell transplant6,8

Sometimes a stem cell transplant is helpful. Healthy stem cells from a donor replace the stem cells in your child’s bone marrow that the chemotherapy destroyed.

(5 of 5)

During maintenance therapy and beyond8

Your child may remain on therapy for a period of time to help prevent relapse. During this time, your child’s doctor may want to keep an eye on their MRD levels.

Your child’s doctor may want to continue frequently monitoring MRD status with clonoSEQ. MRD testing can help you feel secure, knowing that if your child’s ALL returns, their healthcare team can treat it immediately.

Talk to your child’s doctor about clonoSEQ

Here are some questions to help you start a conversation with your child’s doctor.

  • I would like you to order clonoSEQ so we can keep a close eye on my child’s cancer. How do we get started?
  • I heard that clonoSEQ can identify 1 cancer cell out of a million cells with sufficient sample. Why does that matter for my child?
  • What can MRD testing with clonoSEQ tell me about my child’s cancer?
  • How can we get clonoSEQ MRD testing incorporated into my child’s care plan?
  • At what points during the treatment process should my child have a clonoSEQ MRD test?
  • How can we ensure coverage for clonoSEQ testing?

Be sure to check in with your child’s doctor regularly. This way, you can ensure your child is on track with the MRD goals you’ve set together.

Take a look at a sample clonoSEQ report

Sample clonoSEQ Report

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020.
  2. Short NJ, et al. Am J Hematol. 2019;94:257-265.
  3. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  4. Short N, et al. Blood Adv. 2022;6(13):4006-4014.
  5. Wood B, et al. Blood. 2018;131(12):1350-1359.
  6. Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
  1. Pulsipher M, et al. Blood Cancer Discov. 2022;3(1):66-81.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.